05.19.2011-Ventrus Biosciences Inc. (NASDAQ: VTUS; Stock Twits: $VTUS) has three products in development.
They include a potential new prescription drug for the treatment of hemorrhoids, anal fissures, fecal incontinence and other gastro-intestinal disorders.
Ventrus management will be participating in the closing of the NASDAQ market on Thursday, May 19th at 3:50 PM.
The NASDAQ MarketSite Webcam is located at: * VTUS stock has more than doubled since its IPO in December 2010, which makes Ventrus one of the best performing equities in the biotech space which has been exceptionally strong this year;
* VTUS has 3 late-stage compounds in development (2 of which are in late-stage). These treatments address large markets where there are no FDA approved drugs;
* Efficacy and a high level of safety has been well established in Phase II studies to date;
* Multiple important milestones are set to occur over the next 12-18 months that, if achieved, should build further interest in VTUS;
* The design of the Phase III clinical trials for iferanserserin have been recently modified which raises the possibility that the drug could be approved as a 7-day regimen instead of 14 days, which could significantly broaden the potential market.
Rodman Reshaw's biotech analyst Michael Higgins recently raised his price target on VTUS to $25 from $12 owing to recent progress, especially in the clinical development of iferanserin.
No comments:
Post a Comment